Skip to main content

Table 2 Neutralizing antibodies against the SARS-CoV-2 wild type, Alpha, Beta, Delta, and Omicron variants

From: Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine

 

ChAdOx-1 group (N = 24)

BNT162b2 group (N = 22)

Before boosting

4 weeks after boosting

p value

Before boosting

4 weeks after boosting

p value

Wild type

52.8 (36.9–67.2)

97.3 (96.9–97.5)

< 0.0001

53.4 (31.0–66.3)

97.4 (96.9–97.6)

< 0.0001

Alpha (B.1.1.7)

36.6 (23.4–44.6)

94.3 (92.3–96.6)

< 0.0001

39.9 (30.8–51.0)

97.3 (94.8–97.9)

< 0.0001

Beta (B.1.351)

5.2 (−5.4–18.7)

79.9 (68.9–84.7)

< 0.0001

13.7 (3.6–30.5)

93.7 (88.5–95.4)

< 0.0001

Delta (B.1.617.2)

34.3 (17.1–44.7)

95.5 (93.8–96.9)

< 0.0001

44.9 (29.9–53.3)

97.5 (95.0–97.9)

< 0.0001

Omicron (B.1.1.529)

20.8 (14.9–24.4)

26.9 (12.9–46.4)

0.0828

18.8 (16.9–20.5)

31.9 (3.6–66.7)

0.0275

  1. Data are presented as the median (interquartile range, IQR)
  2. Neutralizing antibodies (% inhibition) against the SARS-CoV-2 wild-type, Alpha, Beta, Delta, and Omicron variants before and 4 weeks after boosting with ChAdOx-1 and BNT162b2 in elderly health care workers
Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us